Patient-derived xenograft models: an emerging platform for translational cancer research.
Manuel Hidalgo,Frédéric Amant,Andrew V. Biankin,Eva Budinská,Annette T. Byrne,Carlos Caldas,Robert Clarke,Steven de Jong,Jos Jonkers,Gunhild Mari Mælandsmo,Sergio Roman-Roman,Joan Seoane,Livio Trusolino,Alberto Villanueva +13 more
TL;DR: The current state of the art in this field is summarized, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and a European consortium of PDX models is introduced.
read more
Abstract: Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. Cancer Discov; 4(9); 998–1013. ©2014 AACR .
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao,Joshua M. Korn,Stephane Ferretti,John Monahan,Youzhen Wang,Mallika Singh,Mallika Singh,Chao Zhang,Chao Zhang,Christian Schnell,Guizhi Yang,Yun Zhang,O. Alejandro Balbin,Stephanie Barbe,Hongbo Cai,Fergal Casey,Susmita Chatterjee,Derek Y. Chiang,Shannon Chuai,Shawn Cogan,Scott D. Collins,Ernesta Dammassa,Nicolas Ebel,Millicent Embry,John Green,Audrey Kauffmann,Colleen Kowal,Rebecca Leary,Joseph Lehar,Ying Liang,Alice Loo,Edward Lorenzana,E. Robert McDonald,Margaret E. McLaughlin,Jason Merkin,Ronald Meyer,Tara L. Naylor,Montesa Patawaran,Anupama Reddy,Anupama Reddy,Claudia Roelli,David A. Ruddy,Fernando Salangsang,Francesca Santacroce,Angad P Singh,Yan Tang,Walter Tinetto,Sonja Tobler,Roberto Velazquez,Kavitha Venkatesan,Fabian Von Arx,Hui Qin Wang,Zongyao Wang,Marion Wiesmann,Daniel Wyss,Fiona Xu,Hans Bitter,Peter Atadja,Emma Lees,Francesco Hofmann,En Li,Nicholas Keen,Robert Cozens,Michael Rugaard Jensen,Nancy Pryer,Nancy Pryer,Juliet Williams,William R. Sellers +67 more
TL;DR: The results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities and could potentially improve preclinical evaluation of treatmentmodalities and enhance the ability to predict clinical trial responses.
1.3K
Identification of the tumour transition states occurring during EMT
Ievgenia Pastushenko,Audrey Brisebarre,Alejandro Sifrim,Alejandro Sifrim,Marco Fioramonti,Tatiana Revenco,Soufiane Boumahdi,Alexandra Van Keymeulen,Daniel Brown,Virginie Moers,Sophie Lemaire,Sarah De Clercq,Esmeralda Minguijón,Cédric Balsat,Youri Sokolow,Christine Dubois,Florian De Cock,Samuel Scozzaro,Federico Sopena,Angel Lanas,Nicky D'Haene,Isabelle Salmon,Jean-Christophe Marine,Thierry Voet,Thierry Voet,Panagiota A. Sotiropoulou,Cédric Blanpain +26 more
TL;DR: A large panel of cell surface markers in skin and mammary primary tumours is screened, and the existence of multiple tumour subpopulations associated with different EMT stages are identified: from epithelial to completely mesenchymal states, passing through intermediate hybrid states.
1.3K
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Laura Broutier,Gianmarco Mastrogiovanni,Monique M A Verstegen,Hayley E. Francies,Lena Morrill Gavarró,Charles R. Bradshaw,George E. Allen,Robert Arnes-Benito,Olga Sidorova,Marcia P. Gaspersz,Nikitas Georgakopoulos,Bon-Kyoung Koo,Sabine Dietmann,Susan E. Davies,Raaj K. Praseedom,Ruby Lieshout,Jan N. M. IJzermans,Stephen J. Wigmore,Kourosh Saeb-Parsy,Mathew J. Garnett,Luc J. W. van der Laan,Meritxell Huch +21 more
TL;DR: The wide-ranging biomedical utilities of PLC-derived organoid models in furthering the understanding of liver cancer biology and in developing personalized-medicine approaches for the disease are demonstrated.
The gut–liver axis and the intersection with the microbiome
Anupriya Tripathi,Anupriya Tripathi,Justine W. Debelius,David A. Brenner,Michael Karin,Rohit Loomba,Bernd Schnabl,Bernd Schnabl,Rob Knight +8 more
TL;DR: Gut–liver communications in liver disease is reviewed, exploring the molecular, genetic and microbiome relationships and discussing prospects for exploiting the microbiome to determine liver disease stage and to predict the effects of pharmaceutical, dietary and other interventions at a population and individual level.
Imaging biomarker roadmap for cancer studies.
James P B O'Connor,Eric O. Aboagye,Judith E. Adams,Hugo J.W.L. Aerts,Hugo J.W.L. Aerts,Sally F. Barrington,Ambros J. Beer,Ronald Boellaard,Sarah E. Bohndiek,J. Michael Brady,Gina Brown,David L. Buckley,Thomas L. Chenevert,Laurence P. Clarke,Sandra Collette,Gary Cook,Nandita M. deSouza,John Dickson,Caroline Dive,Jeffrey L. Evelhoch,Corinne Faivre-Finn,Ferdia A. Gallagher,Fiona J. Gilbert,Robert J. Gillies,Vicky Goh,John R. Griffiths,Ashley M. Groves,Steve Halligan,Adrian L. Harris,David J. Hawkes,Otto S. Hoekstra,Erich P. Huang,Brian Hutton,Edward F. Jackson,Gordon C Jayson,Andrew J. I. Jones,Dow-Mu Koh,Denis Lacombe,Philippe Lambin,Nathalie Lassau,Martin O. Leach,Ting-Yim Lee,Edward Leen,Jason S. Lewis,Yan Liu,Mark F. Lythgoe,Prakash Manoharan,Ross J. Maxwell,Kenneth A. Miles,Bruno Morgan,Steve Morris,Tony Ng,Anwar R. Padhani,Geoff J M Parker,Mike Partridge,Arvind P. Pathak,Arvind P. Pathak,Andrew C. Peet,Shonit Punwani,Andrew R. Reynolds,Simon P. Robinson,Lalitha K. Shankar,Ricky A. Sharma,Dmitry Soloviev,Sigrid Stroobants,Daniel C. Sullivan,Stuart A. Taylor,Paul S. Tofts,Gillian M. Tozer,Marcel van Herk,Simon Walker-Samuel,James Wason,Kaye J. Williams,Paul Workman,Thomas E. Yankeelov,Kevin M. Brindle,Lisa M. McShane,Alan Jackson,John C. Waterton +78 more
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.
References
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah,Andrew Roth,Rodrigo Goya,Arusha Oloumi,Gavin Ha,Yongjun Zhao,Gulisa Turashvili,Jiarui Ding,Kane Tse,Gholamreza Haffari,Ali Bashashati,Leah M Prentice,Jaswinder Khattra,Angela Burleigh,Damian Yap,Virginie Bernard,Andrew McPherson,Karey Shumansky,Anamaria Crisan,Ryan Giuliany,Alireza Heravi-Moussavi,Jamie Rosner,Daniel Lai,Inanc Birol,Richard Varhol,Angela Tam,Noreen Dhalla,Thomas Zeng,Kevin C. Ma,Simon K. Chan,Malachi Griffith,Annie Moradian,S.-W. Grace Cheng,Gregg B. Morin,Peter H. Watson,Karen A. Gelmon,Stephen Chia,Suet-Feung Chin,Christina Curtis,Christina Curtis,Oscar M. Rueda,Paul D.P. Pharoah,Sambasivarao Damaraju,John R. Mackey,Kelly Hoon,Timothy T. Harkins,Vasisht Tadigotla,Mahvash Sigaroudinia,Philippe Gascard,Thea D. Tlsty,Joseph F. Costello,Irmtraud M. Meyer,Connie J. Eaves,Wyeth W. Wasserman,Steven J.M. Jones,Steven J.M. Jones,David G. Huntsman,David G. Huntsman,Martin Hirst,Carlos Caldas,Marco A. Marra,Samuel Aparicio +61 more
TL;DR: It is shown that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes, and for the first time in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population is determined.
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz,Luis A. Diaz,Richard Thomas Williams,Jian Wu,Jian Wu,Isaac Kinde,J. Randolph Hecht,Jordan Berlin,Benjamin L. Allen,Ivana Bozic,Johannes G. Reiter,Johannes G. Reiter,Martin A. Nowak,Kenneth W. Kinzler,Kelly S. Oliner,Bert Vogelstein +15 more
TL;DR: Results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner, which explains why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
J. I. Johnson,S. Decker,Daniel W. Zaharevitz,Larry Rubinstein,J M Venditti,S Schepartz,S Kalyandrug,Michaele C. Christian,Susan G. Arbuck,Melinda G. Hollingshead,Edward A. Sausville +10 more
TL;DR: For 39 agents with both xenograft data and Phase II clinical trials results available, in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting doubt on the correspondence of the pre-clinical models to clinical results.
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler,Aik Choon Tan,Colin D. Weekes,Antonio Jimeno,Stephen Leong,Todd M. Pitts,John J. Arcaroli,Wells A. Messersmith,S. Gail Eckhardt +8 more
TL;DR: This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding,Matthew J. Ellis,Shunqiang Li,David E. Larson,Ken Chen,John W. Wallis,Chris Harris,Michael D. McLellan,Robert S. Fulton,Lucinda Fulton,Rachel Abbott,Jeremy Hoog,David J. Dooling,Daniel C. Koboldt,Heather K. Schmidt,Joelle Kalicki,Qunyuan Zhang,Lei Chen,Ling Lin,Michael C. Wendl,Joshua F. McMichael,Vincent Magrini,Lisa Cook,Sean McGrath,Tammi L. Vickery,Elizabeth L. Appelbaum,Katherine DeSchryver,Sherri R. Davies,Therese Guintoli,Li-li Lin,Robert J. Crowder,Yu Long Tao,Jacqueline E. Snider,Scott M. Smith,Adam F. Dukes,Gabriel E. Sanderson,Craig Pohl,Kim D. Delehaunty,Catrina Fronick,Kimberley A. Pape,Jerry S. Reed,Jody S. Robinson,Jennifer S. Hodges,William Schierding,Nathan D. Dees,Dong-Wei Shen,Devin P. Locke,Madeline E. Wiechert,James M. Eldred,Josh B. Peck,Benjamin J. Oberkfell,Justin T. Lolofie,Feiyu Du,Amy Hawkins,Michelle D O'Laughlin,Kelly E. Bernard,Mark L. Cunningham,Glendoria Elliott,Mark D. Mason,Dominic M. Thompson,Jennifer Ivanovich,Paul J. Goodfellow,Charles M. Perou,George M. Weinstock,Rebecca Aft,Mark A. Watson,Timothy J. Ley,Richard K. Wilson,Elaine R. Mardis +68 more
TL;DR: The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within thePrimary tumour.
1.2K
Related Papers (5)
Hui Gao,Joshua M. Korn,Stephane Ferretti,John Monahan,Youzhen Wang,Mallika Singh,Mallika Singh,Chao Zhang,Chao Zhang,Christian Schnell,Guizhi Yang,Yun Zhang,O. Alejandro Balbin,Stephanie Barbe,Hongbo Cai,Fergal Casey,Susmita Chatterjee,Derek Y. Chiang,Shannon Chuai,Shawn Cogan,Scott D. Collins,Ernesta Dammassa,Nicolas Ebel,Millicent Embry,John Green,Audrey Kauffmann,Colleen Kowal,Rebecca Leary,Joseph Lehar,Ying Liang,Alice Loo,Edward Lorenzana,E. Robert McDonald,Margaret E. McLaughlin,Jason Merkin,Ronald Meyer,Tara L. Naylor,Montesa Patawaran,Anupama Reddy,Anupama Reddy,Claudia Roelli,David A. Ruddy,Fernando Salangsang,Francesca Santacroce,Angad P Singh,Yan Tang,Walter Tinetto,Sonja Tobler,Roberto Velazquez,Kavitha Venkatesan,Fabian Von Arx,Hui Qin Wang,Zongyao Wang,Marion Wiesmann,Daniel Wyss,Fiona Xu,Hans Bitter,Peter Atadja,Emma Lees,Francesco Hofmann,En Li,Nicholas Keen,Robert Cozens,Michael Rugaard Jensen,Nancy Pryer,Nancy Pryer,Juliet Williams,William R. Sellers +67 more
Andrea Bertotti,Giorgia Migliardi,Francesco Galimi,Francesco Sassi,Davide Torti,Claudio Isella,Davide Corà,Federica Di Nicolantonio,Michela Buscarino,Consalvo Petti,Dario Ribero,Nadia Russolillo,Andrea Muratore,Paolo Massucco,Alberto Pisacane,Luca Molinaro,Emanuele Valtorta,Andrea Sartore-Bianchi,Mauro Risio,Lorenzo Capussotti,Marcello Gambacorta,Salvatore Siena,Enzo Medico,Anna Sapino,Silvia Marsoni,Paolo M. Comoglio,Alberto Bardelli,Livio Trusolino +27 more